Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have yet to see a single indication that we have been thrown off-track.
Welcome to the room, dorf1. Uh, yes, I'm a real person. A created version of me would likely not claim an open buy order as modest as is mine. But I really hope that my buy order fills, because I'm only focused on the potential of having so many more shares when management shifts us out of neutral, and into drive.
I expect that we could announce positive regulatory news in terms of authorization or approval to treat CMML and/or covid.
I also expect that management will recall their loaned shares.
Both events will significantly increase demand for shares.
Management currently does not have enough shares in the market to meet the demand.
A 5:1 forward stock split will increase the supply of shares available to meet demand, without causing dilution. This is the stripped-down simplified version of the answer to your question. It gets more complicated, but I decided not to develop the following answer.
I think management plans to declare a 5:1 forward stock split, which would give us an OS of (119,080,135 x 5 =) 595,400,675 shares. If they conclude a business combination, they have said the entity we form with our partner will receive two times our current OS, which means they would get 238,160,270 shares, leaving us with 357,240,405 shares, or 60% of the shares.
Unless we get a Priority Review Voucher, or funds from an Advanced Purchase Agreement, we will need an Equity Offering. As it stands, the above would indicate that we can only sell about 53.5M shares to retain control.
I think we have an open shelf registration to permit the sell of about $80M worth of stock. So we would need just under $1.50 per share by resuming the Controlled Equity Offering.
I wonder if Mary Lou Retton is a compassionate use candidate for lenz.
https://www.yahoo.com/entertainment/former-olympic-gymnast-mary-lou-215335047.html
I agree that management has contrived to place us where we are. I noted before that Durrant prepared our last two 10-Q's himself, and he could certainly have prepared the second quarter 10-Q in a timely fashion, unless there was a reason to get us to the Pink Limited trading venue. Like you say, I think this was an intentional move.
But it appears to me that management plans to file the delinquent 10-Q, and uplist, rather than delist.
And yes, I include a merger on our list of catalysts.
But, management is solely and totally in control of the other catalysts that will force a short covering, that being the recall of their loaned shares, and the forward stock split. Those are also legal reasons brokerages will have to cover short positions.
In addition, though, I really think our covid EUA will be approved, either in the US, and/or in the UK. And I think it is also likely that we will get CMML approval from Australia. This will entice buying, and further increase demand for shares.
Far from grasping at straws, this is the execution of their objectives, and will lead to accomplishing the items I noted on our list of catalysts.
I have a lunch money investment into more shares which, if filled, will add ~50% to my shares. I simply can't afford more, or I would. I'm just really glad that you have continued to add.
"El degüello (Spanish: El toque a degüello) is a bugle call, notable in the United States for its use as a march by Mexican Army buglers during the 1836 Siege and Battle of the Alamo to signal that the defenders of the garrison would receive no quarter by the attacking Mexican Army under General Antonio López de Santa Anna."
https://en.wikipedia.org/wiki/El_Deg%C3%BCello
CPT Almaron Dickinson, an ancestor to my wife, likely heard the bugle call at the Alamo in 1836.
"Show no quarter" is what I say now, from my own Alamo. And I interpret management's efforts, including the timing of the 10-Q's, as giving short sellers no escape from their fate.
I'm convinced management's design of the stock play will be wildly successful, when enacted.
Shares can't be liquidated if they can't be bought. So I have an obvious lack of understanding about the EM. But it's irrelevant to me, because I don't think it will pertain to us.
I can only speak about what I can see. And to me, this is the prelude to a stock play. I say that as objectively as I can.
I've got one open buy order at $0.002, anticipating that we will forward split at 5:1. The rest of my open orders are sells ranging from sub- $5, up to $250, and I'll still have shares left if everything fills.
Management will also be able to have shares to sell, as the result of the forward split. And the recall of their loaned shares will force demand by forcing the purchase of shares that were borrowed.
I think THAT is what they want. We just need regulatory approval, from anywhere, for anything, and we've got outstanding covid and CMML results that we know of.
Why do you say that, 1upandaway?
I didn't see a wild dump of shares just now. And I'm glad I didn't. I still think we're looking for a stock play.
I have no idea about when HGEN entered a 15 day grace period. But, I also have no idea why only 36.46M shares are still reported as held by DTC.
But it still seems to me that the company has a desire and a right to recall their loaned shares, and to declare a 5:1 forward stock split.
However, I have no idea of how to participate in stock transactions on the Expert Market, if it comes to that. But if those of us who WANT to sell, can be paired with those who HAVE to buy, I'd be okay with that.
Such a helter-skelter transaction structure is hard to internalize, when I think we could be looking at regulatory authorizations/approvals for CMML and Covid. I can't believe that the company would get to that point, and not ensure that they have an Exchange for new buyers.
"I am really conflicted on this issue."
None of the material I have read, justifying the use of new drugs with no possibility of knowing what the long term effects of the drugs may be, considers that the disease, itself, could be new, as we see with the novel coronavirus, which has claimed over 1.2M American lives.
With a novel and lethal virus, developing and using novel therapeutics is the only chance there is of saving lives.
Here's an interesting insight from the New Jersey health department written in March of 2020 in this regard.
"The World Health Organization (WHO) has decided to name the disease caused by the novel coronavirus "COVID-19" and refers to the virus that causes it as the "COVID-19 virus." CO for corona, VI for virus, D for disease, and 19 for the year the outbreak was first recognized, late in 2019."
https://covid19.nj.gov/faqs/coronavirus-information/about-the-virus/what-is-the-official-name-of-the-novel-coronavirus#:~:text=The%20World%20Health%20Organization%20(WHO,first%20recognized%2C%20late%20in%202019.
However, there was already an existing law, the 21st Century Cures Act, which detailed the provisions for MCM (Medical Countermeasures) cures.
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/21st-century-cures-act-mcm-related-cures-provisions
There was a MCM priority review voucher associated with this law, but it expired last week. But I mention this law as an avenue for us, in the event it may prove useful. I hope that we just get our EUA this week, and don't need an alternative way of getting it.
I seem to Recall that we have seven catalysts, not six. Could be a "cut and paste" error on my part.
Or, maybe we are planning to announce news that will lead to relisting on NASDAQ, and then announcing the remainder of our news once we are there. Ideally, and most likely, the NASDAQ Appeals Panel has been kept abreast of all our continuing developments, and is anticipating our upcoming moves. This strategy could also impact Baudax, and result in their meeting NASDAQ continued listing requirements.
The goal I would most like to meet is getting approval of our EUA to treat covid. That has a substantial potential to generate block-buster levels of recurring revenue. But even a cancer treatment approval would give me great personal appreciation for what lenz can contribute.
Your referenced article indicates, "On Oct. 3, the Food and Drug Administration (FDA) authorized the updated COVID-19 vaccine by Novavax for people ages 12 and older."
https://www.yahoo.com/lifestyle/novavax-covid-vaccine-224757507.html
However, the mRNA vaccines from Pfizer and Moderna were authorized on Sept 11th. So the Pfizer and Moderna vaccines got first-to-market authorization, and sold 4 million vaccines, before Novavax got out of the starting gate. Again.
https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating
Novavax still shouldn't move to your buy list, according to Motley Fool.
https://www.fool.com/investing/2023/10/07/this-could-be-novavaxs-big-opportunity/
But if the lenz/vaccine/anti-viral cocktail proves successful, that will destroy the Pfizer and Moderna vaccine market, and allow Novavax to gain that market share, in my opinion.
Baudax's corporate controller, Jillian Dilmore, has resigned. I was a funds administrator in the Army, but Jillian has scary-skills dealing with merger subs, etc., and her Deloitte & Touche background was evident. I felt more comfortable reading clinical trial data, than trying to understand what Jillian was doing. She was impressive.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000119312523251966/d416304d8k.htm
But also impressive is how this whole restructuring is taking place in the pre-Q3 filing period. I can understand holding up the second quarter 10-Q in preparation of a stock play, executed from the Pink Limited trading venue. I saw both Gracell and Baudax submitted Registration Statements, and how those became effective on the same day. But how Humanigen, Gracell, and Baudax (and Novavax or PCI Pharma?) are going to fit together, as I think they somehow will, is an orchestration I look forward to watching. I note that at this point, neither Baudax nor Humanigen have a Chief Financial Officer, and I wonder if Kevin Xie will assume those functions.
The reporter in your referenced article notes, "Of the 37 drugs approved by the FDA last year, 24 (about 65%) were approved based on just one study, according to a paper published in JAMA Network Open."
https://nypost.com/2023/08/24/fda-fast-tracking-approval-of-new-drugs-fewer-trials-less-info/
The reporter laments what he described as, "...a significant departure from the more rigorous vetting process the agency (FDA) was previously known for."
I am really conflicted on this issue. The first reported case of covid in the United States was in March 2020.
"Although we found that SARS-CoV-2 likely began spreading in New Orleans mid-February, 2020, the first official COVID-19 case was not reported until March 9th."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872376/#:~:text=Although%20we%20found%20that%20SARS,reported%20until%20March%209th.
And it was just one year later when Humanigen reported the topline data (TLD) from the LIVE-AIR trial.
“Mayo Clinic is pleased to have been part of the investigation of lenzilumab from the earliest days of the development program in COVID-19 and are excited by these data,” said Andrew Badley, MD, Professor of Infectious Diseases, and Professor and Chair of the Department of Molecular Medicine at Mayo Clinic. “If lenzilumab is authorized for emergency use by FDA, and based on our clinical trial experience to date, it may then be considered a part of our treatment armamentarium for newly hospitalized patients with COVID-19.”
https://www.businesswire.com/news/home/20210329005301/en/
To this day, I agree with Dr. Badley. Lenz should be the standard of care in the treatment of covid, and I hope that it will be, once our EUA is authorized, which I hope will be soon. I wished my wife's doctors would have agreed to her getting lenz as a compassionate use treatment before TLD was released.
On the other hand, I am very unsettled by the lack of long term treatment data regarding mRNA vaccines, especially when they are approved for infants that are 6 months old, and we are seeing altered immune systems in patients suffering with Long Covid.
https://www.cdc.gov/vaccines/covid-19/downloads/covid-19-immunization-schedule-ages-6months-older.pdf
How do we best safeguard our very young, and prevent the alteration of their immune response systems? If it is really necessary to vaccinate these infants, would the lenz/vaccine/anti-viral cocktail be a better alternative? The Novavax vaccine is approved for patients 12 years and older.
https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-novavax-covid-19-vaccine-formulated-better-protect-against-currently
If there really is a need to vaccinate infants, I would at least be more reassured if lenz was administered to help protect their innate immune systems. This could go from being a rhetorical discussion, to one that is very practical, once we have our EUA, and the medical community looks to expand the benefit offered by lenz.
Interesting article regarding our damaged healthcare infrastructure, which could really become problematic.
"Nursing schools are turning away thousands of applicants during a major nursing shortage. Here’s why
Tami Luhby, CNN
Thu, October 5, 2023...
Staffing shortages are the main reason why nursing schools are not able to accept more students who want to become registered nurses...
The national median salary for nursing school professors with master’s degrees is just under $89,000, according to the nursing college association. But the median salary for advanced practice registered nurses, who hold graduate degrees, is $120,000...
Many hospitals are experiencing their own staffing shortages and are relying on short-term contract nurses or travel nurses. This reduces their capacity to train students, said Marie Ann Marino, dean of the Thomas Jefferson University College of Nursing in Philadelphia..."
https://www.yahoo.com/finance/news/nursing-schools-turning-away-thousands-095224269.html
It should be noted that there is a disparity, in my view, of the reports regarding the Novavax vaccine.
I think the following is over-stated. "This shot is effective at preventing infection with Omicron strains of the virus."
(second bullet point)
https://www.yahoo.com/lifestyle/covid-shot-more-effective-against-204422261.html
A bit more clarity is provided here. "The updated vaccine addresses currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death."
(second paragraph)
https://www.fda.gov/news-events/press-announcements/fda-authorizes-updated-novavax-covid-19-vaccine-formulated-better-protect-against-currently
To me, it's an important distinction, because I think the Novavax vaccine COULD BECOME effective at preventing covid pneumonia infection, if it is used in the lenz/vaccine/anti-viral cocktail. If that should be proved to be the case, then I think the whole doctrine of annual reformulations of mRNA vaccines, which cause continued mutations, can be discarded, which I think it should be.
I guess you missed where I said, "Heck, I can't even remember what, if anything, comes after "Q" right now." I don't know what their plan is regarding the second quarter financials. I can see a stock-related reason for the delay. But we can't be planning on remaining Pink Limited. For all I know, we could be seeing a completely new ticker, resulting from a merger or business combination. Or maybe we'll see the Q2 and Q3 10-Q's released at the same time.
I don't think we will see that. I think we'll see the second quarter 10-Q after our stock play is executed. Why unnecessarily draw attention to a dire financial situation, when it will be resolved by the recall of our loaned shares, and the 5:1 forward stock split?
I agree. Anyone who can look at the list of catalysts I have pinned here, and think that management needs "to do something," has a serious issue in comprehension skills.
">CAR-T enhancement
>Our merger with Baudax
>The resubmission of our EUA application to the FDA with copy to MHRA in UK
>Tentative regulatory approval for lenz to treat CMML, granted by Australia's Therapeutic Goods Administration
>A finding to continue the study of lenz based on results from the first 20 patients in the aGvHD trial, which could prove to be a cure for certain cancers
>The declaration of a 5:1 forward stock split, depending perhaps on concluding a planned business combination."
And not only could Novavax be considered as a potential partner, but, if "CAR-T enhancement" doesn't encompass Gracell, then they, too, could be distinguished as a possible catalyst.
Man, please don't say that management needs to do more, when they are limited in their communications. I already had to add CAR-T enhancement to our list of catalysts, and yesterday's news of the FDA's authorization of Nuvaxovid reminds me of my favorite choice of Novavax as a merger partner.
https://thehill.com/homenews/4236455-novavaxs-covid-19-vaccine-gets-fda-authorization/?utm_source=ground.news&utm_medium=referral
Heck, I can't even remember what, if anything, comes after "Q" right now.
Seriously, though, the thought of us inoculating 6 month old babies with mRNA vaccines causes me a great deal of trepidation. This is especially true when I see instances of how the government filters news, such as they did in regards to gain of function, which they have effectively blamed on the Wuhan Institute of Virology (WIV), and absolved not only the NIH of responsibility, the IG wouldn't even cite the role of Eco-Health in acting on our behalf.
I would really like to see results of lenz, administered after a Novavax or Janssen vaccine, with an anti-viral and whatever polyclonal antibodies management has determined. Maybe this will be a true vaccine, and eliminate annual, and therefore perpetually late and mistargeted, mRNA vaccines.
I guess the second quarter 10-Q was more relevant to Baudax, than to Gracell. And we probably won't see the third quarter 10-Q for another month, or so. But, along with our enhanced CAR-T patent, the three companies could carve out a niche as a CAR-T cartel with some unique characteristics.
Congratulations to Novavax on the FDA authorization of their vaccine for the 2023-2024 treatment year.
https://www.yahoo.com/news/fda-signs-off-novavax-covid-184916733.html
It seems the processing of their saponin adjuvant may be responsive to lenz, if not just replaced by lenz.
https://www.novavax.com/science-technology/matrix-m-adjuvant-technology
I hope this opens the door to lenz to be used in the US as part of our patented lenz/vaccine/anti-viral cocktail, which could prove to be the world's first covid vaccine, in the true sense of the word.
"METHODS FOR TREATING CORONAVIRUS INFECTION AND RESULTING INFLAMMATION-INDUCED LUNG INJURY
Publication number: 20230109208
Abstract: The present invention provides methods for treating a subject infected with 2019 coronavirus (SARS-CoV-2) comprising administering to the subject a therapeutically effective amount of a GM-CSF antagonist or a therapeutically effective amount of a GM-CSF antagonist and a second drug, including an anti-viral agent, an anti-SARS-CoV-2 vaccine, and serum containing human polyclonal antibodies to SARS-CoV-2.
Type: Application
Filed: March 8, 2021
Publication date: April 6, 2023
Applicant: HUMANIGEN, INC.
Inventors: Cameron DURRANT, Dale CHAPPEL"
https://patents.justia.com/assignee/humanigen-inc
It would be a major expansion of lenzilumab's market opportunity, to be used not only as a treatment, but as a preventative, as well. In fact, after the initial traditional lenz/vaccine/anti-viral treatment, or the initial infection, lenz may be the only drug needed to prevent and/or to treat future covid pneumonia infections.
I'm glad to hear that, Bill! Good luck to all of us, and to the millions of patients lenz can save.
Speaking of batting orders, the number 2 slot is currently held by a post discussing why we may be seeing a 5:1 forward stock split declared, along with a recall of our loaned shares.
Batter up!!
In a post Humanigen features on their X site, we see the following.
"Invest with Hisa
@HisaApp
·
15h
Earnings Calendar: US Stocks Set to Release Their Financials Today, October 2nd 2023
Before Market Open:
1. $ATNXQ Athenex Inc
2. $TUP Tupperware Brands
3. $IMBIQ iMedia Brands
4. $LOVE Lovesac
5. $RAD Rite Aid Corp
6. $HGEN Humanigen"
https://twitter.com/search?q=humanigen&src=typed_query&f=live
There is nothing atypical about this. It's pretty standard to see this. As each projected report date comes and goes, the dates just keep getting adjusted.
So I don't know whether to expect to see a 10-Q, or just a Press Release. Either way, I hope we will see the recall of our loaned shares announced, and the declaration of a 5:1 forward stock split. This could provide management with the opportunity to sell the $80M+ worth of stock we have available from our open shelf registration, to desperate short sellers who will be forced to buy, by the recall of our loaned shares.
“Necessity is the mother of invention.”
- Plato
"Combining the political pushback that is developing, the increased hypervirulence and anti-biotic resistance of certain emerging infections, 2020 levels of Covid detected in wastewater sampling, and additional safety and efficacy in support of LIVE-AIR results, we may very well see our EUA approved, not only overseas, but in the United States, as well."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172886198
Of course I didn't see the 10-Q before the Gracell presentations. We're Pink Limited.
https://www.securitieslawyer101.com/2013/otc-markets-otc-pink-sheets-uplisting-going-public/
The ability to provide a strategic reasoning is beyond me. But I'll look forward to seeing the reason unfold, when it does.
Duh!!
Unfortunately, not only is a WHO-directed Pandemic Treaty a frightening prospect, it is also one that could actually be required.
Why the hell would I say something like that?
It's because that on a micro level, at least in this country, we can't believe what we are permitted to see.
Take the case of the illegal and unsafe operation of the bio-lab discovered by a code enforcement officer in Reedley, CA, which I mentioned in real-time.
"'Fairly shocking': Secret medical lab in California stored bioengineered mice laden with COVID."
https://www.usatoday.com/story/news/nation/2023/07/31/illegal-lab-california-infectious-mice/70502532007/
I disagreed that the discovery was just fairly shocking. An American biotech company operating such an illegal bio-weapon lab in China would be considered by the Chinese as an act of war, because it is.
But in California, we see that Prestige was related to an entity, then housed in their facility, that received a $360,000 tax credit allocation from the Governor.
"As recently discovered, Prestige Biotech is registered in the State of Nevada, but unlicensed to conduct business within the State of California. Code enforcement officials from the City of Reedley spoke to Xiuqin Yao, President of Prestige Biotech, as identified via emails and court documents. Ms. Yao informed authorities that the company was the largest creditor of Universal Meditech (UMI), Inc. which filed for bankruptcy. UMI had been relocated from the City of Fresno to the Reedley warehouse following an electrical fire, and when UMI ceased operations. According to NBC News, “Prestige Biotech was a creditor to UMI and identified as its successor, according to court documents.”
A document released on March 24, 2019 by Governor Newsom’s Office of Business and Economic Development, a California Competes tax credit allocation agreement of $360,000 was cemented with UMI.*
https://politicalhotwire.com/t/reedley-chinese-covid-lab-received-tax-credit-of-360-000-from-gov-newsom%E2%80%99s-%E2%80%98go-biz%E2%80%99.272670/
But even at the national government level, the government treats us like children being told by their parents that Santa Claus is real. Take the HHS Inspector General's finding about the role of the NIH in funding gain of function research.
"NIH had concluded that these studies did not qualify as “gain-of-function” research that requires a special HHS review because the hybrid viruses weren’t expected to be more dangerous to mammals than the starting viruses. But it stipulated that EcoHealth should “immediately” report any unexpected growth of the hybrid viruses to NIH.
NIH has faulted EcoHealth for failing to promptly report this unexpected growth in some experiments."
https://www.science.org/content/article/federal-watchdog-finds-problems-nih-oversight-grant-funding-bat-virus-research-china
Are we really to believe that we were funding gain of function research on developing virus mutations that were expected to be less dangerous than the starting virus?
The NIH's National Library of Medicine reports the following Gain-of-Function Research: Ethical Analysis.
"Gain-of-function (GOF) research involves experimentation that aims or is expected to (and/or, perhaps, actually does) increase the transmissibility and/or virulence of pathogens."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996883/#:~:text=Gain%2Dof%2Dfunction%20(GOF,and%2For%20virulence%20of%20pathogens.
The IG cannot absolve the NIH of their failure to oversee the development of this virus, when the whole point of Gain of Function research is to increase the virulence and transmissibility of viruses, so that treatment protocols could be developed in advance.
Humanigen has suffered terribly from the government's abuse of discretionary authority. We have endured, nonetheless.
But I want to see that we have done more than just endure. It looks like the stage is set, and it's our turn in the spotlight. I hope that it is.
It would be really nice to get our EUA today, before the government shutdown.
And I remind you that the tort lawyer used ACTIV-5 clinical trial to refute the LIVE-AIR trial data. So I hope management sues the hell out of the class action lawyer.
I distinguished CAR-T enhancement as a catalyst for our list because lenz, and perhaps ifab, could improve that treatment method far beyond just what we may be seeing reported by Gracell and Baudax.
But Dale and Durrant aren't doing the manufacturing themselves. We have zero infrastructure, CMC, or desire, to do so. So the question should be what value will our partners bring, not what the price would be to shareholders.
But, we may be looking for different, not just the same things, from Baudax and Gracell. For example, we may be looking at Baudax as a partner, but at Gracell as a business combination. So the cost benefits may be different. I've speculated about that, in a post about ADR's (American Depositary Receipts). But there is far too little evidence to say more about the possibility.
Potential partners report reaching milestones?
"Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate"
https://www.sec.gov/Archives/edgar/data/1826492/000110465923104946/tm2327037d1_ex99-1.htm
"Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors"
https://www.sec.gov/Archives/edgar/data/1780097/000119312523246376/d512346dex991.htm
I hinted about my expectation in this regard.
"A $1M per patient treatment cost, and the treatment is ineffective for 30% of the treated patients.
Sounds like a job for lenzilumab.
But surely not, right? How could lenz possibly eliminate most of the treatment cost, and also improve the complete response rate for patients, when Humanigen's stock price it teetering on one cent?
Dare I to think that this unrealized potential presents promise almost beyond comprehension? Could share price be transient, yet result in lenzilumab demonstrating results that are robust and durable?
This is just about one of the many active opportunities for lenz. I'm here for the realization of all of lenzilumab's opportunities.
And political power is not a factor for this indication. Nor does Big Pharma regulatory influence come into play. When a product is as good as lenz, it can't be denied for everything, and forever."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172881158
This is actually about TeraImmune's 'TI-168.' We've seen proof of our interest in Baudax/TeraImmune through our investment. However, I haven't seen evidence of lenz enabling TI-168 to perform so well, so I didn't say more than I did.
https://investorplace.com/2023/09/why-is-baudax-bio-bxrx-stock-up-75-today/
I found this study conclusion fascinating.
"Thursday, September 28, 2023
SARS-CoV-2 infects coronary arteries, increases plaque inflammation...
SARS-CoV-2, the virus that causes COVID-19, can directly infect the arteries of the heart and cause the fatty plaque inside arteries to become highly inflamed, increasing the risk of heart attack and stroke, according to a study funded by the National Institutes of Health."
https://www.nih.gov/news-events/news-releases/sars-cov-2-infects-coronary-arteries-increases-plaque-inflammation
However, I'm still seeing inflammation after having the atherectomies on my left leg almost one month ago.
I agreed with you previously on this. I think I've been infected by chutzpah. The currently circulating strains of the infection are the Gracell and the Recall variants. Both can be highly infectious.
In the last minute of Kevin Xie's presentation to Cantor yesterday, he did acknowledge that Gracell is looking for a US partnership.
https://wsw.com/webcast/cantor19/grcl/2082696
I think he may have heard of Humanigen, and knows a little bit about what we do...since he was a member of our Board of Directors.
I wasn't surprised to hear what Kevin said. It only confirms what I had deduced. But it did increase my confidence in entering into a merger or business combination with them.
I finally got the buy order in at the forward stock split price that I wanted to test. Any such fill opportunity could be just seconds in length, so if it happens, maybe I'll get lucky.
I get the sense that management is ready to pull the trigger on the recall of their loaned shares, and to also give us a buffet of positive news on multiple fronts.
Too little, too late.
"The Centers for Disease Control and Prevention approved the latest vaccine two weeks ago, and the new shots became available to the general public within the last week or so. But many nursing homes will not begin inoculations until well into October or even November, though infections among this vulnerable population are rising, to nearly 1%, or 9.7 per 1,000 residents in mid-September from a low of 2.2 per 1,000 residents in mid-June.
“The distribution of the new COVID-19 vaccine is not going well,” said Chad Worz, the CEO of the American Society of Consultant Pharmacists. “Older adults in those settings are certainly the most vulnerable and should have been prioritized.”
https://www.yahoo.com/news/covid-infections-rise-nursing-homes-175204664.html
The death rate in this vulnerable population is projected to be 4.4 times higher than the current covid death rate. Those deaths could be prevented, if lenz was approved, and could be even better in those nursing home residents who already had covid once or twice previously, and if lenz could be used as a pre-or post- exposure prophylactic.
And this is the standard operating procedure we want to memorialize? Continue to sacrifice lives for annual fall campaigns of updated vaccines that then need to be distributed nationally? It doesn't have to be this way, and it shouldn't be this way.
"It makes far more sense to program an appropriate immune response to a respiratory infection, whether it is viral, fungal, parasitic, or bacterial in nature."
It appears that Veru, perhaps at the FDA's suggestion, may also be thinking of using sabizabulin in a broader market focused on treating Acute Respiratory Distress Syndrome.
"Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult
September 26, 2023 "
https://www.bloomberg.com/press-releases/2023-09-26/veru-reaches-agreement-with-fda-on-new-phase-3-clinical-trial-for-sabizabulin-for-broader-indication-hospitalized-adult
This is the company that reported outlandish mortality benefit in trying to get sabizabulin authorized for covid. The FDA Declined to grant their EUA.
"Veru's EUA ambitions crash after FDA declines to authorize its COVID treatment
By Max BayerMar 3, 2023 11:17am"
https://www.fiercebiotech.com/biotech/verus-eua-ambitions-crash-after-fda-declines-authorize-its-covid-treatment
I wonder if the FDA suggested the same thing to Humanigen. I happen to think a broader market use makes sense, as I said, perhaps even extending to non-viral respiratory infections.
Hopefully, it's a moot point. The additional safety and efficacy data we have obtained since LIVE-AIR will likely prove sufficient for the FDA to grant our resubmitted EUA, especially with covid hospitalizations and deaths on the rise from a highly mutated covid variant.
I am thrilled to see you get the prices you got today, eb.
I really would like to see our 2nd quarter 10-Q released this week, with updates on all 7 of the catalysts I am looking for.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172877542
I'd like to see either Durrant or Dale pick up a board seat, and to also see Ed Jordan named to our board, too.
Transformative times for us, I sincerely hope.
I tried to, but my deposit last week STILL has settled.
I think the main reason the second quarter 10-Q has been delayed was to inflict maximum pain on short sellers once management recalls their loaned shares.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172803990
But there's a lot of moving parts management is dealing with, which may explain the Notices of Effectiveness both appearing today for Baudax and Gracell, plus other items I listed in the catalysts I'm expecting, to include our EUA and potential approval from Australia for CMML.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172877542